Oxford Coronavirus Vaccine Induces Immune Response in Early Test

Zydus Cadila begins human clinical trials of its ZyCoV-D vaccine

A coronavirus vaccine being developed by British pharmaceutical AstraZeneca and Oxford University showed a robust immune response in the early phases of its trial.

The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and the induction of strong immune responses in both parts of the immune system.

"We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period", University of Oxford Professor Andrew Pollard said.

"Again, it's a first step, but to have a vaccine trialled in a reasonable sized cohort of people and showing an immune response is very encouraging". Antibodies are able to prevent the virus from infecting cells when it is initially contracted, according to the release.

"Even so, we need to have far more investigate prior to we can affirm the vaccine effectively safeguards from SARS-CoV-2 (COVID-19) infection, and for how extensive any protection lasts", he explained.

The main objective of this trial was to ensure that the vaccine is safe enough to administer, but larger trials - which will extend to countries where levels of coronavirus are particularly high - will seek to determine whether it is effective.

"We now need to move into larger-scale real-world trials".

The vaccine, ChAdOx1 nCoV-19, now known as AZN1222, was co-invented by Vaccitech and Oxford University's Jenner Institute.

Reported reactions were more common among patients who received the coronavirus vaccine than those who received the control, which was a meningitis vaccine. It has said it will not seek to profit from the vaccine during the pandemic.

Study enrollment took place between April 23 and May 21, and included 1,077 participants from 18 to 55 years old who had not previously tested positive for the coronavirus.

While these are hopeful results, there's still a long way to go before we have a viable vaccine at our fingertips. As part of CSIRO's preclinical study of Oxford's vaccine candidate, our scientists evaluated the efficacy of one versus two doses as well as administration of the vaccine via a nasal delivery and/or an intramuscular injection. Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India. The company had last week started clinical trials of its COVID-19 vaccine candidate with the first human dosing.

"People are looking for antibodies that, in the lab, will block infection in a culture system, called 'neutralizing antibodies.' And that sounds very good", said Gallo, who is also the co-founder and worldwide scientific adviser of the Global Virus Network.